Media.Player

Bacterial peptides to attenuate infection or autoimmune disease

總結

Ivaylo Ivanov, Ph.D.

技術優勢

Does not require colonization with live bacteria which may be detrimental in immune compromised individualsProduces a localized effect and could be used in patients with malfunctioning peripheral lymph node systems or as a targeted therapyBecause the technology does not require colonization, the effect could be transient in nature, thus allowing acute induction of a strengthened immune response during cold and flu season or in response to acute outbreaksPatent information:Patent PendingTech Ventures Reference: IR CU14287

技術應用

Increase the immune response in individuals who are immune compromisedAid in the development of inactivating antibodies to downregulate Th17 activity in subjects with autoimmune disordersEngineer specific SFB strains that contain antigens capable of promoting immune healthCreate peptide adjuvants to increase the effectiveness of vaccines

詳細技術說明

Ivaylo Ivanov, Ph.D.

*Abstract

None

*Inquiry

Peter GolikovColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR

CU14287

*Principal Investigation

*Publications

Y Goto, C Panea, G Nakato, A Cebula, C Lee, MG Diez, TM Laufer, L Ignatowicz, II Ivanov. "Segmented filamentous bacteria antigens presented by intestinal dendritic cells drive mucosal Th17 cell differentiation" Immunity, 2014 Mar 27;40(4):594-607.

國家/地區

美國